Castle Biosciences, Inc.
CSTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $83 | $86 | $88 | $86 |
| % Growth | -3.6% | -2% | 1.9% | – |
| Cost of Goods Sold | $19 | $18 | $16 | $16 |
| Gross Profit | $64 | $69 | $72 | $70 |
| % Margin | 77.5% | 79.5% | 81.4% | 81.3% |
| R&D Expenses | $13 | $13 | $13 | $12 |
| G&A Expenses | $0 | $23 | $22 | $20 |
| SG&A Expenses | $56 | $58 | $59 | $50 |
| Sales & Mktg Exp. | $0 | $35 | $37 | $30 |
| Other Operating Expenses | $2 | $2 | $28 | $4 |
| Operating Expenses | $71 | $73 | $100 | $66 |
| Operating Income | -$7 | -$4 | -$28 | $4 |
| % Margin | -8.2% | -4.9% | -31.7% | 4.7% |
| Other Income/Exp. Net | $6 | $4 | $2 | $4 |
| Pre-Tax Income | -$0 | -$0 | -$26 | $8 |
| Tax Expense | $0 | -$5 | -$0 | -$2 |
| Net Income | -$1 | $5 | -$26 | $10 |
| % Margin | -0.6% | 5.2% | -29.4% | 11.1% |
| EPS | -0.017 | 0.16 | -0.9 | 0.34 |
| % Growth | -110.8% | 117.8% | -364.7% | – |
| EPS Diluted | -0.02 | 0.15 | -0.9 | 0.32 |
| Weighted Avg Shares Out | 25 | 29 | 29 | 28 |
| Weighted Avg Shares Out Dil | 29 | 30 | 29 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $3 | $30 | $6 |
| EBITDA | $5 | $3 | $4 | $14 |
| % Margin | 6.3% | 3.8% | 4% | 15.9% |